Ascentage Pharma Group International
Hong Kong Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Ascentage Pharma Group International (6855.HK) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies targeting apoptosis regulators for cancers, chronic hepatitis B, and age-related diseases; its core pipeline includes nine clinical-stage candidates such as the third-generation BCR-ABL inhibitor olverembatinib (HQP1351/耐立克®) for drug-resistant chronic myeloid leukemia, the Bcl-2 selective inhibitor lisaftoclax (APG-2575), the dual Bcl-2/Bcl-xL inhibitor pelcitoclax (APG-1252), the MDM2-p53 inhibitor alrizomadlin (APG-115), IAP inhibitors, next-generation tyrosine kinase inhibitors including ALK and FAK inhibitors, and epigenome-modifying agents like an EED inhibitor. The company conducts over 40 clinical trials across the US, Australia, Europe, and China, including eleven registrational trials with two FDA-regulated; it serves primarily hematologic malignancies such as chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and multiple myeloma, as well as solid tumors and other indications. Founded in 2009 and headquartered in Suzhou, China, with additional operations in Rockville, Maryland, USA, Ascentage Pharma maintains global partnerships with entities including Takeda, AstraZeneca, MSD, Pfizer, and Innovent Biologics. Recent developments include the closing of a US$75 million equity investment from Takeda in June 2024 as part of a US$1.3 billion licensing deal for olverembatinib; US FDA clearance for a global Phase III trial of olverembatinib in February 2024; a US$190.1 million financing round in July 2025; and a US$126 million Nasdaq IPO in January 2025 under ticker AAPG, alongside ongoing collaborations such as with AstraZeneca for APG-2575 in CLL/SLL.
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026
Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting
ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances
Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting
Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA
ASCO 2023 | Ascentage Pharma to Present Results from 4 Studies Highlighting Extended Therapeutic Potential of Lead Drug Candidates
AACR 2023 | Ascentage Pharma Presents Results from Three Studies Underscoring Exploratory Efforts in Potential New Indications